Does the media favor URGN or CRNX?

In the previous week, Crinetics Pharmaceuticals had 10 more articles in the media than Urogen Pharma. MarketBeat recorded 16 mentions for Crinetics Pharmaceuticals and 6 mentions for Urogen Pharma. Urogen Pharma's average media sentiment score of 1.48 beat Crinetics Pharmaceuticals' score of 0.86 indicating that Urogen Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Urogen Pharma 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Crinetics Pharmaceuticals 7 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, LNTH or URGN?

Lantheus has higher revenue and earnings than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantheus $1.54B 4.27 $233.56M $4.14 24.36 Urogen Pharma $109.79M 20.15 -$153.49M -$1.98 N/A

Is LNTH or URGN more profitable?

Lantheus has a net margin of 17.69% compared to Urogen Pharma's net margin of -51.73%. Lantheus' return on equity of 28.10% beat Urogen Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Lantheus 17.69% 28.10% 14.35% Urogen Pharma -51.73% N/A -43.79%

Does the media refer more to LNTH or URGN?

In the previous week, Lantheus had 2 more articles in the media than Urogen Pharma. MarketBeat recorded 8 mentions for Lantheus and 6 mentions for Urogen Pharma. Urogen Pharma's average media sentiment score of 1.48 beat Lantheus' score of 1.38 indicating that Urogen Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Urogen Pharma 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BLTE or URGN?

In the previous week, Urogen Pharma had 2 more articles in the media than Belite Bio. MarketBeat recorded 6 mentions for Urogen Pharma and 4 mentions for Belite Bio. Urogen Pharma's average media sentiment score of 1.48 beat Belite Bio's score of 0.00 indicating that Urogen Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Urogen Pharma 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, LQDA or URGN?

Liquidia has higher revenue and earnings than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liquidia $158.32M 38.90 -$68.92M $1.37 50.23 Urogen Pharma $109.79M 20.15 -$153.49M -$1.98 N/A

Is LQDA or URGN more profitable?

Liquidia has a net margin of 30.74% compared to Urogen Pharma's net margin of -51.73%. Liquidia's return on equity of 149.65% beat Urogen Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Liquidia 30.74% 149.65% 36.30% Urogen Pharma -51.73% N/A -43.79%

Does the media refer more to LQDA or URGN?

In the previous week, Liquidia had 9 more articles in the media than Urogen Pharma. MarketBeat recorded 15 mentions for Liquidia and 6 mentions for Urogen Pharma. Urogen Pharma's average media sentiment score of 1.48 beat Liquidia's score of 0.75 indicating that Urogen Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 5 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Urogen Pharma 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to URGN or DFTX?

In the previous week, Urogen Pharma had 1 more articles in the media than Definium Therapeutics. MarketBeat recorded 6 mentions for Urogen Pharma and 5 mentions for Definium Therapeutics. Urogen Pharma's average media sentiment score of 1.48 beat Definium Therapeutics' score of 0.82 indicating that Urogen Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Urogen Pharma 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Definium Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Urogen Pharma (URGN) Competitors

$45.22 +0.80 (+1.80%)

As of 03:39 PM Eastern

Compare

URGN vs. CRNX, LNTH, BLTE, LQDA, and DFTX

Should you buy Urogen Pharma stock or one of its competitors? Urogen Pharma's main competitors and comparable companies include Crinetics Pharmaceuticals (CRNX), Lantheus (LNTH), Belite Bio (BLTE), Liquidia (LQDA), and Definium Therapeutics (DFTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Urogen Pharma compare to Crinetics Pharmaceuticals?

Urogen Pharma (NASDAQ:URGN) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

Urogen Pharma has higher revenue and earnings than Crinetics Pharmaceuticals. Urogen Pharma is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Urogen Pharma	$109.79M	20.15	-$153.49M	-$1.98	N/A
Crinetics Pharmaceuticals	$7.70M	1,170.54	-$465.32M	-$5.04	N/A

91.3% of Urogen Pharma shares are owned by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. 4.8% of Urogen Pharma shares are owned by insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Urogen Pharma has a beta of 1.57, suggesting that its share price is 57% more volatile than the broader market. Comparatively, Crinetics Pharmaceuticals has a beta of 0.08, suggesting that its share price is 92% less volatile than the broader market.

In the previous week, Crinetics Pharmaceuticals had 10 more articles in the media than Urogen Pharma. MarketBeat recorded 16 mentions for Crinetics Pharmaceuticals and 6 mentions for Urogen Pharma. Urogen Pharma's average media sentiment score of 1.48 beat Crinetics Pharmaceuticals' score of 0.86 indicating that Urogen Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Urogen Pharma	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Crinetics Pharmaceuticals	7 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Urogen Pharma presently has a consensus target price of $50.38, indicating a potential upside of 11.33%. Crinetics Pharmaceuticals has a consensus target price of $81.00, indicating a potential downside of 4.65%. Given Urogen Pharma's stronger consensus rating and higher possible upside, equities analysts clearly believe Urogen Pharma is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24

Urogen Pharma has a net margin of -51.73% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. Urogen Pharma's return on equity of 0.00% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Urogen Pharma	-51.73%	N/A	-43.79%
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%

Summary

Urogen Pharma beats Crinetics Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Urogen Pharma compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Urogen Pharma (NASDAQ:URGN) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability and institutional ownership.

Lantheus has higher revenue and earnings than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.27	$233.56M	$4.14	24.36
Urogen Pharma	$109.79M	20.15	-$153.49M	-$1.98	N/A

In the previous week, Lantheus had 2 more articles in the media than Urogen Pharma. MarketBeat recorded 8 mentions for Lantheus and 6 mentions for Urogen Pharma. Urogen Pharma's average media sentiment score of 1.48 beat Lantheus' score of 1.38 indicating that Urogen Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Urogen Pharma	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantheus has a net margin of 17.69% compared to Urogen Pharma's net margin of -51.73%. Lantheus' return on equity of 28.10% beat Urogen Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	17.69%	28.10%	14.35%
Urogen Pharma	-51.73%	N/A	-43.79%

Lantheus presently has a consensus price target of $108.11, suggesting a potential upside of 7.19%. Urogen Pharma has a consensus price target of $50.38, suggesting a potential upside of 11.33%. Given Urogen Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Urogen Pharma is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

99.1% of Lantheus shares are owned by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are owned by institutional investors. 1.7% of Lantheus shares are owned by company insiders. Comparatively, 4.8% of Urogen Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Lantheus has a beta of -0.03, suggesting that its stock price is 103% less volatile than the broader market. Comparatively, Urogen Pharma has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market.

Summary

Lantheus beats Urogen Pharma on 9 of the 17 factors compared between the two stocks.

How does Urogen Pharma compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and Urogen Pharma (NASDAQ:URGN) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, institutional ownership, valuation, risk, analyst recommendations and earnings.

Belite Bio has a net margin of 0.00% compared to Urogen Pharma's net margin of -51.73%. Urogen Pharma's return on equity of 0.00% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-11.84%	-11.62%
Urogen Pharma	-51.73%	N/A	-43.79%

Belite Bio has higher earnings, but lower revenue than Urogen Pharma. Belite Bio is trading at a lower price-to-earnings ratio than Urogen Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A
Urogen Pharma	$109.79M	20.15	-$153.49M	-$1.98	N/A

0.5% of Belite Bio shares are held by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are held by institutional investors. 13.3% of Belite Bio shares are held by company insiders. Comparatively, 4.8% of Urogen Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Belite Bio has a beta of -1.23, indicating that its stock price is 223% less volatile than the broader market. Comparatively, Urogen Pharma has a beta of 1.57, indicating that its stock price is 57% more volatile than the broader market.

Belite Bio presently has a consensus price target of $205.80, indicating a potential upside of 21.09%. Urogen Pharma has a consensus price target of $50.38, indicating a potential upside of 11.33%. Given Belite Bio's higher possible upside, research analysts plainly believe Belite Bio is more favorable than Urogen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Urogen Pharma had 2 more articles in the media than Belite Bio. MarketBeat recorded 6 mentions for Urogen Pharma and 4 mentions for Belite Bio. Urogen Pharma's average media sentiment score of 1.48 beat Belite Bio's score of 0.00 indicating that Urogen Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Urogen Pharma	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Urogen Pharma beats Belite Bio on 10 of the 15 factors compared between the two stocks.

How does Urogen Pharma compare to Liquidia?

Liquidia (NASDAQ:LQDA) and Urogen Pharma (NASDAQ:URGN) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

In the previous week, Liquidia had 9 more articles in the media than Urogen Pharma. MarketBeat recorded 15 mentions for Liquidia and 6 mentions for Urogen Pharma. Urogen Pharma's average media sentiment score of 1.48 beat Liquidia's score of 0.75 indicating that Urogen Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	5 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Urogen Pharma	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Liquidia has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market. Comparatively, Urogen Pharma has a beta of 1.57, indicating that its stock price is 57% more volatile than the broader market.

Liquidia currently has a consensus target price of $98.08, indicating a potential upside of 42.54%. Urogen Pharma has a consensus target price of $50.38, indicating a potential upside of 11.33%. Given Liquidia's higher possible upside, research analysts plainly believe Liquidia is more favorable than Urogen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.45
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Liquidia has higher revenue and earnings than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	38.90	-$68.92M	$1.37	50.23
Urogen Pharma	$109.79M	20.15	-$153.49M	-$1.98	N/A

Liquidia has a net margin of 30.74% compared to Urogen Pharma's net margin of -51.73%. Liquidia's return on equity of 149.65% beat Urogen Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	30.74%	149.65%	36.30%
Urogen Pharma	-51.73%	N/A	-43.79%

64.5% of Liquidia shares are held by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are held by institutional investors. 25.6% of Liquidia shares are held by insiders. Comparatively, 4.8% of Urogen Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Liquidia beats Urogen Pharma on 11 of the 16 factors compared between the two stocks.

How does Urogen Pharma compare to Definium Therapeutics?

Urogen Pharma (NASDAQ:URGN) and Definium Therapeutics (NASDAQ:DFTX) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings and institutional ownership.

Urogen Pharma has a beta of 1.57, indicating that its stock price is 57% more volatile than the broader market. Comparatively, Definium Therapeutics has a beta of 2.23, indicating that its stock price is 123% more volatile than the broader market.

Urogen Pharma has higher revenue and earnings than Definium Therapeutics. Urogen Pharma is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Urogen Pharma	$109.79M	20.15	-$153.49M	-$1.98	N/A
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A

91.3% of Urogen Pharma shares are held by institutional investors. Comparatively, 27.9% of Definium Therapeutics shares are held by institutional investors. 4.8% of Urogen Pharma shares are held by insiders. Comparatively, 2.4% of Definium Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Definium Therapeutics has a net margin of 0.00% compared to Urogen Pharma's net margin of -51.73%. Urogen Pharma's return on equity of 0.00% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Urogen Pharma	-51.73%	N/A	-43.79%
Definium Therapeutics	N/A	-84.01%	-63.66%

Urogen Pharma presently has a consensus target price of $50.38, suggesting a potential upside of 11.33%. Definium Therapeutics has a consensus target price of $63.00, suggesting a potential upside of 64.84%. Given Definium Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Definium Therapeutics is more favorable than Urogen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Urogen Pharma had 1 more articles in the media than Definium Therapeutics. MarketBeat recorded 6 mentions for Urogen Pharma and 5 mentions for Definium Therapeutics. Urogen Pharma's average media sentiment score of 1.48 beat Definium Therapeutics' score of 0.82 indicating that Urogen Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Urogen Pharma	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Definium Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Urogen Pharma beats Definium Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Urogen Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding URGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

URGN vs. The Competition

Export

Metric	Urogen Pharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.21B	$12.30B	$7.25B	$12.92B
Dividend Yield	N/A	2.60%	2.53%	8.56%
P/E Ratio	-22.85	789.77	273.84	25.43
Price / Sales	20.15	956.14	675.54	123.68
Price / Cash	N/A	92.66	76.98	52.08
Price / Book	-16.70	12.42	12.90	6.17
Net Income	-$153.49M	$2.83B	$3.48B	$349.24M
7 Day Performance	-0.55%	2.26%	-0.42%	-1.46%
1 Month Performance	17.26%	5.06%	6.41%	2.47%
1 Year Performance	133.61%	9.28%	24.92%	15.80%

Urogen Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
URGN Urogen Pharma	2.4639 of 5 stars	$45.22 +1.8%	$50.38 +11.4%	+127.4%	$2.21B	$109.79M	N/A	200	Positive News
CRNX Crinetics Pharmaceuticals	1.5923 of 5 stars	$84.84 0.0%	$81.00 -4.5%	N/A	$9.00B	$7.70M	N/A	210	News Coverage Analyst Forecast
LNTH Lantheus	3.9216 of 5 stars	$100.82 0.0%	$108.11 +7.2%	+82.3%	$6.58B	$1.54B	24.35	1,193	Positive News
BLTE Belite Bio	2.3064 of 5 stars	$156.69 -3.1%	$205.80 +31.3%	+145.8%	$6.48B	N/A	N/A	10	Analyst Forecast
LQDA Liquidia	4.2803 of 5 stars	$71.36 +1.2%	$98.08 +37.4%	+143.8%	$6.31B	$158.32M	52.09	50	Trending News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:URGN) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Urogen Pharma (URGN) Competitors

URGN vs. CRNX, LNTH, BLTE, LQDA, and DFTX

How does Urogen Pharma compare to Crinetics Pharmaceuticals?

Summary

How does Urogen Pharma compare to Lantheus?

Summary

How does Urogen Pharma compare to Belite Bio?

Summary

How does Urogen Pharma compare to Liquidia?

Summary

How does Urogen Pharma compare to Definium Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

URGN vs. The Competition

Urogen Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Urogen Pharma (URGN) Competitors

URGN vs. CRNX, LNTH, BLTE, LQDA, and DFTX

How does Urogen Pharma compare to Crinetics Pharmaceuticals?

Which has better earnings and valuation, URGN or CRNX?

Do institutionals and insiders believe in URGN or CRNX?

Which has more volatility & risk, URGN or CRNX?

Does the media favor URGN or CRNX?

Do analysts rate URGN or CRNX?

Is URGN or CRNX more profitable?

Summary

How does Urogen Pharma compare to Lantheus?

Which has higher earnings & valuation, LNTH or URGN?

Does the media refer more to LNTH or URGN?

Is LNTH or URGN more profitable?

Do analysts recommend LNTH or URGN?

Do insiders & institutionals hold more shares of LNTH or URGN?

Which has more risk and volatility, LNTH or URGN?

Summary

How does Urogen Pharma compare to Belite Bio?

Is BLTE or URGN more profitable?

Which has preferable earnings and valuation, BLTE or URGN?

Do institutionals and insiders believe in BLTE or URGN?

Which has more risk & volatility, BLTE or URGN?

Do analysts recommend BLTE or URGN?

Does the media refer more to BLTE or URGN?

Summary

How does Urogen Pharma compare to Liquidia?

Does the media refer more to LQDA or URGN?

Which has more volatility & risk, LQDA or URGN?

Do analysts recommend LQDA or URGN?

Which has higher earnings & valuation, LQDA or URGN?

Is LQDA or URGN more profitable?

Do insiders and institutionals hold more shares of LQDA or URGN?

Summary

How does Urogen Pharma compare to Definium Therapeutics?

Which has more risk and volatility, URGN or DFTX?

Which has higher earnings and valuation, URGN or DFTX?

Do insiders & institutionals hold more shares of URGN or DFTX?

Is URGN or DFTX more profitable?

Do analysts prefer URGN or DFTX?

Does the media refer more to URGN or DFTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

URGN vs. The Competition

Urogen Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools